Stübig, T <br/><br/>
JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.  [electronic resource] 

 -  Leukemia  Aug 2014 
 - 1736-8 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2014.86  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Female<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Janus Kinases--antagonists & inhibitors<br/>Male<br/>Middle Aged<br/>Nitriles<br/>Primary Myelofibrosis--drug therapy<br/>Pyrazoles--adverse effects<br/>Pyrimidines<br/>Transplantation, Homologous